J A Arnaiz
- The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawalsJ A Arnaiz
Clinical Pharmacology, UASP, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
Eur J Clin Pharmacol 57:89-91. 2001..Withdrawal of a drug from the market for safety reasons is a serious and sometimes complex decision. The scientific evidence supporting drug withdrawals in the past years is critically appraised...
- A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patientsJ Mallolas
Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
Rev Clin Esp 207:427-32. 2007....
- Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapyE Martinez
Unit of Infectious Diseases, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic Universitari, Barcelona, Spain
AIDS 15:1261-8. 2001..To assess the incidence and risk factors for hepatotoxicity associated with nevirapine...
- Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell countsE De Lazzari
Biostatistic Unit, Hospital Clinic, University of Barcelona, Spain
HIV Med 9:221-6. 2008..It is unclear whether this higher risk also applies to stable virologically suppressed patients starting NcART...
- Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART studySean Emery
Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
J Infect Dis 197:1133-44. 2008..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
- Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-upJens D Lundgren
Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
J Infect Dis 197:1145-55. 2008..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
- Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trialW M El-Sadr
Ann Intern Med 149:289-99. 2008..Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy...